Maria Maddalena Tumedei

Dr. Maria Maddalena Tumedei

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Michela CortesiMichela Cortesi
Michela Cortesi
Michele ZanoniMichele Zanoni
Michele Zanoni
FPFrancesca Pirini
Francesca Pirini
MTMaria Maddalena Tumedei
Maria Maddalena Tumedei
SRSara Ravaioli
Sara Ravaioli
SBSara Bravaccini
Sara Bravaccini
Pancreatic ductal adenocarcinoma (PDAC) has one of the most dismal prognoses of all cancers due to its late manifestation and resistance to current therapies. Accumulating evidence has suggested that the malignant behavior of this cancer is mainly influenced by the associated strongly immunosuppressive, desmoplastic microenvironment and by the relatively low mutational burden. PDAC develops and progresses through a multi-step process. Early in tumorigenesis, cancer cells must evade the effects of cellular senescence, which slows proliferation and promotes the immune-mediated elimination of pre-malignant cells. The role of senescence as a tumor suppressor has been well-established; however, recent evidence has revealed novel pro-tumorigenic paracrine functions of senescent cells towards their microenvironment. Understanding the interactions between tumors and their microenvironment is a growing research field, with evidence having been provided that non-tumoral cells composing the tumor microenvironment (TME) influence tumor proliferation, metabolism, cell death, and therapeutic resistance. Simultaneously, cancer cells shape a tumor-supportive and immunosuppressive environment, influencing both non-tumoral neighboring and distant cells. The overall intention of this review is to provide an overview of the interplay that occurs between senescent and non-senescent cell types and to describe how such interplay may have an impact on PDAC progression. Specifically, the effects and the molecular changes occurring in non-cancerous cells during senescence, and how these may contribute to a tumor-permissive microenvironment, will be discussed. Finally, senescence targeting strategies will be briefly introduced, highlighting their potential in the treatment of PDAC.

23 March 2014 in Breast Cancer Research and Treatment
Verified
Journal Article
Closed access
PDF file
DAD. Amadori
D. Amadori
PSP. Serra
P. Serra
SBSara Bravaccini
Sara Bravaccini
AFAlberto Farolfi
Alberto Farolfi
MPM. Puccetti
M. Puccetti
NMN. Masalu
N. Masalu

8 August 2020 in Diagnostics
Verified
Journal Article
Open access
PDF file
MPMichela Palelschi
Michela Palelschi
RMROBERTA MALTONI
ROBERTA MALTONI
SRSara Ravaioli
Sara Ravaioli
AVAlessandro Vagheggini
Alessandro Vagheggini
FMFrancesca Mannozzi
Francesca Mannozzi
SBSara Bravaccini
Sara Bravaccini
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expression of progesterone receptor (PR) and Ki67, assessed by immunohistochemistry, in 71 ABC patients treated with CDK4/6i and analyzed the impact of these markers on progression-free survival (PFS). The majority of patients 63/71 (88.7%) received palbociclib, 4 (5.6%) received ribociclib, and 4 (5.6%) received abemaciclib. A higher median value of Ki67 was observed in cases undergoing second-line treatment (p = 0.047), whereas the luminal B subtype was more prevalent (p = 0.005). In the univariate analysis of the first-line setting, luminal A subtype showed a trend towards a correlation with a longer PFS (p = 0.053). A higher continuous Ki67 value led to a significantly shorter PFS. When the interaction between pathological characteristics and line of treatment was considered, luminal B subtype showed a significantly (p = 0.043) worse outcome (Hazard Ratio (HR) 2.84; 1.03–7.82 95% Confidence Interval (CI)). PFS in patients undergoing endocrine therapy plus CDK4/6i was inversely correlated with Ki67 expression but not with PR, suggesting that tumor proliferation has a greater impact on cell cycle inhibitors combined with endocrine therapy than PR expression.

27 March 2018 in BMC Cancer
Verified
Journal Article
Open access
PDF file
GBGiuseppe Bronte
Giuseppe Bronte
ARAndrea Rocca
Andrea Rocca
SRSara Ravaioli
Sara Ravaioli
MPMaurizio Puccetti
Maurizio Puccetti
MTMaria Maddalena Tumedei
Maria Maddalena Tumedei
SBSara Bravaccini
Sara Bravaccini
Androgen receptor (AR) is widely expressed in breast cancer (BC) but its role in estrogen receptor (ER)-positive tumors is still controversial. The AR/ER ratio has been reported to impact prognosis and response to antiestrogen endocrine therapy (ET). We assessed whether AR in primary tumors and/or matched metastases is a predictor of efficacy of first-line ET in advanced BC. Patients who had received first-line ET (2002–2011) were recruited, while those given concomitant chemotherapy or trastuzumab or pretreated with > 2 lines of chemotherapy were excluded. ER, progesterone receptor (PgR), Ki67 and AR expression were assessed by immunohistochemistry, and HER2 mainly by fluorescent in-situ hybridization. Cut-offs of 1 and 10% immunostained cells were used to categorize AR expression. Among 102 evaluable patients, biomarkers were assessed in primary tumors in 70 cases and in metastases in 49, with 17 patients having both determinations. The overall concordance rate between primary tumors and metastases was 64.7% (95% CI 42%-87.4%) for AR status. AR status did not affect TTP significantly, whereas PgR and Ki67 status did. AR/PgR ≥0.96 was associated with a significantly shorter TTP (HR = 1.65, 95% CI 1.05-2.61, p = 0.028). AR status in primary tumors or metastases was not associated with progressive disease (PD) as best response. In contrast, Ki67 ≥ 20% and PgR < 10% showed a statistically significant association with PD as best response. AR expression does not appear to be useful to predict the efficacy of ET in advanced BC, whereas Ki67 and PgR exert a greater impact on its efficacy.

3 July 2022 in Expert Opinion on Therapeutic Targets
Verified
Journal Article
Closed access
Michela CortesiMichela Cortesi
Michela Cortesi
Michele ZanoniMichele Zanoni
Michele Zanoni
RMROBERTA MALTONI
ROBERTA MALTONI
SRSara Ravaioli
Sara Ravaioli
MTMaria Maddalena Tumedei
Maria Maddalena Tumedei
SBSara Bravaccini
Sara Bravaccini
Breast cancer (BC) is the most common diagnosed cancer and the second leading cause of cancer-associated death in women, with the triple negative (TNBC) subtype being characterized by the poorest p...

10 March 2015 in Cytopathology
Verified
Journal Article
Closed access
PDF file
SBSara Bravaccini
Sara Bravaccini
MTMaria Maddalena Tumedei
Maria Maddalena Tumedei
Paola UliviPaola Ulivi
Paola Ulivi
WZW. Zoli
W. Zoli
DCDaniele Calistri
Daniele Calistri
MPM. Puccetti
M. Puccetti